Skip to main content
AAN.com

Abstract

Objective: To determine whether patients with ALS–frontotemporal lobar dementia (FTLD) have a shorter survival and are less compliant with recommended treatments than those with ALS who have normal executive and behavioral function (classic ALS).
Methods: Survival analysis from ALS symptom onset to death included 81 of 100 consecutive patients who could be classified definitely as ALS with abnormal executive or behavioral function or as classic ALS. Criteria were defined for compliance with noninvasive positive-pressure ventilation (NPPV) and percutaneous endoscopic gastrostomy (PEG).
Results: Median survival was 2 years 4 months for the 28 patients with FTLD and 3 years 3 months for the 53 patients with classic ALS (relative hazard for death 1.93, CI 1.09 to 3.43; p = 0.024). However, the relative hazard associated with FTLD (1.49) in the multivariate model was diminished by the association of FTLD with bulbar onset and older age and was not significant in this sample size. With bulbar onset, median survival was 2 years 0 months for the 14 with ALS-FTLD and 2 years 10 months for the 10 with classic ALS (relative hazard for death 2.78, CI 1.02 to 7.55; p = 0.045), and older age was not a significant risk. Noncompliance with NPPV and PEG were 75% and 72% in ALS-FTLD, respectively, vs 38% and 31% in classic ALS (relative risks 2.00 and 2.34; p = 0.013 and 0.022).
Conclusions: Survival is significantly shorter among patients with ALS-FTLD than with classic ALS. Furthermore, patients with ALS-FTLD are twice as likely to be noncompliant.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Majoor-Krakauer D, Willems PJ, Hofman A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin Genet 2003;63:83–101.
2.
Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: A review. Brain 1981;104:217–247.
3.
Bak TH, Hodges JR. Cognition, language and behaviour in motor neurone disease: Evidence of frontotemporal dysfunction. Dement Geriatr Cogn Disord 1999;10(suppl 1):29–32.
4.
Strong MJ, Grace GM, Orange JB, Leeper HA, Menon RS, Aere C. A prospective study of cognitive impairment in ALS. Neurology 1999;53:1665–1670.
5.
Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60:1094–1097.
6.
Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293–299.
7.
Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
8.
Cummings JL. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 1997;48(Suppl 6):S10–S16.
9.
Heaton RK, Chelune FJ, Talley JL, Kay GG, Curtis G. Wisconsin Card Sorting Test (WCST) Manual: Revised and Expanded. Odessa: Psychological Assessment Resources; 1993.
10.
Delis DC, Kaplan E, Kramer JH. Delis–Kaplan Executive Function System. San Antonio: Psychological Corp.; 2001.
11.
Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. San Antonio: Psychological Corp.; 2000.
12.
Wechsler D. Wechsler Memory Scale. 3rd ed. San Antonio: Psychological Corp.; 1997.
13.
Kaplan K. The Boston Naming Test. Philadelphia: Lea & Febiger; 1982.
14.
Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio: Psychological Corp.; 1997.
15.
Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.
16.
Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol 1995;242:695–698.
17.
Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 1997;127:450–453.
18.
Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 1999;164:82–88.

Information & Authors

Information

Published In

Neurology®
Volume 65Number 11December 13, 2005
Pages: 1774-1777
PubMed: 16344521

Publication History

Published online: December 12, 2005
Published in print: December 13, 2005

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

R. K. Olney, MD
From the ALS Treatment and Research Center (Drs. Olney, Murphy, Langmore, and Lomen-Hoerth, Ms. Forshew, and Ms. Garwood), Memory and Aging Center (Dr. Miller), Department of Neurology, and Department of Epidemiology and Biostatistics (Dr. Kohn), University of California, San Francisco, San Francisco.
J. Murphy, PhD
From the ALS Treatment and Research Center (Drs. Olney, Murphy, Langmore, and Lomen-Hoerth, Ms. Forshew, and Ms. Garwood), Memory and Aging Center (Dr. Miller), Department of Neurology, and Department of Epidemiology and Biostatistics (Dr. Kohn), University of California, San Francisco, San Francisco.
D. Forshew, RN, BSN
From the ALS Treatment and Research Center (Drs. Olney, Murphy, Langmore, and Lomen-Hoerth, Ms. Forshew, and Ms. Garwood), Memory and Aging Center (Dr. Miller), Department of Neurology, and Department of Epidemiology and Biostatistics (Dr. Kohn), University of California, San Francisco, San Francisco.
E. Garwood, BS
From the ALS Treatment and Research Center (Drs. Olney, Murphy, Langmore, and Lomen-Hoerth, Ms. Forshew, and Ms. Garwood), Memory and Aging Center (Dr. Miller), Department of Neurology, and Department of Epidemiology and Biostatistics (Dr. Kohn), University of California, San Francisco, San Francisco.
B. L. Miller, MD
From the ALS Treatment and Research Center (Drs. Olney, Murphy, Langmore, and Lomen-Hoerth, Ms. Forshew, and Ms. Garwood), Memory and Aging Center (Dr. Miller), Department of Neurology, and Department of Epidemiology and Biostatistics (Dr. Kohn), University of California, San Francisco, San Francisco.
S. Langmore, PhD
From the ALS Treatment and Research Center (Drs. Olney, Murphy, Langmore, and Lomen-Hoerth, Ms. Forshew, and Ms. Garwood), Memory and Aging Center (Dr. Miller), Department of Neurology, and Department of Epidemiology and Biostatistics (Dr. Kohn), University of California, San Francisco, San Francisco.
M. A. Kohn, MD
From the ALS Treatment and Research Center (Drs. Olney, Murphy, Langmore, and Lomen-Hoerth, Ms. Forshew, and Ms. Garwood), Memory and Aging Center (Dr. Miller), Department of Neurology, and Department of Epidemiology and Biostatistics (Dr. Kohn), University of California, San Francisco, San Francisco.
C. Lomen-Hoerth, MD, PhD
From the ALS Treatment and Research Center (Drs. Olney, Murphy, Langmore, and Lomen-Hoerth, Ms. Forshew, and Ms. Garwood), Memory and Aging Center (Dr. Miller), Department of Neurology, and Department of Epidemiology and Biostatistics (Dr. Kohn), University of California, San Francisco, San Francisco.

Notes

Address correspondence and reprint requests to Dr. Richard K. Olney, 350 Parnassus Avenue, #500, San Francisco, CA 94117; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Factors associated with adherence to noninvasive positive pressure ventilation in amyotrophic lateral sclerosis, PLOS ONE, 19, 5, (e0302515), (2024).https://doi.org/10.1371/journal.pone.0302515
    Crossref
  2. Development and Validation of the Korean Version of the Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen (ECAS-K), Journal of Clinical Neurology, 19, 5, (454), (2023).https://doi.org/10.3988/jcn.2022.0403
    Crossref
  3. Norwegian version of the Edinburgh cognitive and behavioural ALS screen: Construct validity, internal consistency, inter-rater, and test-retest reliability, PLOS ONE, 18, 5, (e0285307), (2023).https://doi.org/10.1371/journal.pone.0285307
    Crossref
  4. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration, Acta Neuropathologica Communications, 11, 1, (2023).https://doi.org/10.1186/s40478-023-01705-8
    Crossref
  5. The complexity of multidisciplinary respiratory care in amyotrophic lateral sclerosis, Breathe, 19, 3, (220269), (2023).https://doi.org/10.1183/20734735.0269-2022
    Crossref
  6. Cognitive impairment is associated with gait variability and fall risk in amyotrophic lateral sclerosis, European Journal of Neurology, 30, 10, (3056-3067), (2023).https://doi.org/10.1111/ene.15936
    Crossref
  7. Neuropsychological impairment in amyotrophic lateral sclerosis–frontotemporal spectrum disorder, Nature Reviews Neurology, 19, 11, (655-667), (2023).https://doi.org/10.1038/s41582-023-00878-z
    Crossref
  8. Brain PET Imaging, PET Clinics, 18, 1, (123-133), (2023).https://doi.org/10.1016/j.cpet.2022.09.010
    Crossref
  9. ALS-plus related clinical and genetic study from China, Neurological Sciences, 44, 10, (3557-3566), (2023).https://doi.org/10.1007/s10072-023-06843-4
    Crossref
  10. Language deficits in primary lateral sclerosis: cortical atrophy, white matter degeneration and functional disconnection between cerebral regions, Journal of Neurology, 271, 1, (431-445), (2023).https://doi.org/10.1007/s00415-023-11994-7
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share